2023年1月4日

．(圖片:美國東部標準時間2023年1月04日07:37)加州帕洛阿爾托——(美國商業新聞)——Medable公司，行業領先的以患者為中心的臨床試驗技術平台，今天宣布與非營利組織Every Cure合作，該組織於9月與克林頓全球倡議正式啟動，以擴大創新的“藥物再利用”研究方法，以確定罕見疾病的治療方法。據估計，大約有9000種疾病沒有fda批準的治療方法，需要很多年——通常是幾十年——和數十億美元才能實現治愈。每一個治愈的使命是拯救更多的生命，通過確定現有藥物的新用途，並進行最有前途的治療方法的臨床試驗，以評估其有效性，以獲得fda的批準和/或超說明書臨床使用。Every Cure由David Fajgenbaum博士共同創立，他在2010年在醫學院時被診斷出患有Castleman病。卡斯曼病是一種罕見的疾病，在他被診斷時，沒有已知的治療方法，也沒有藥物在研發中。正如法根鮑姆在回憶錄《追逐我的治愈方法》(Chasing My Cure)中所描述的那樣，他發現了一種現有的藥物西羅莫司(sirolimus)，可以被重新用於治療Castleman。因為他的發現，法根鮑姆博士活了八年多，病情得到緩解。他的團隊已經重複了10次這種方法，為已批準的卡斯曼病、癌症和COVID-19治療方法確定新用途。他推出了“每一種療法”，複製和擴大他的研究過程，重新利用現有的療法來治療罕見疾病。 “David Fajgenbaum’s story is an inspiration, and it reinforces the critical need for innovation in clinical research,” said Dr. Michelle Longmire , CEO and co-founder of Medable. “We live in an era of exponential improvements in medicine, but traditional clinical trials are a bottleneck in the system – and only yield 50 new FDA-approved treatments per year. With new technologies and new research techniques, we believe it’s possible to drastically increase the number of therapies in development – and Every Cure will be an important leader in driving that change.” Medable will partner with Every Cure by providing specialized software and services to conduct global, remote clinical trials for drug repurposing candidates. Medable’s software-as-a-service (SaaS) platform has been used in more than 300 decentralized and hybrid clinical trials, serving over one million patients and research participants in 60 countries. Medable customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions – helping to accelerate delivery of effective therapies to patients. Dr. Fajgenbaum unveiled Every Cure’s plans at the Clinical Global Initiative meeting held in New York, where Fajgenbaum was a featured speaker. Every Cure has developed a tool called the MATRIX that uses machine learning and AI to identify and rank promising treatments. A pilot study uncovered 106 promising drug repurposing opportunities in the first 147 diseases. In partnership with Medable, Every Cure will conduct clinical trials of the most promising and high impact opportunities for FDA-approval of an existing drug with a new indication. “Patients around the world die every day from diseases that could have been cured by a drug sitting on the shelf at their local pharmacy,” said Dr. Fajgenbaum. “Every Cure is dedicated to unlocking all diseases that existing drugs can treat by developing a comprehensive open-source database of drug repurposing opportunities and launching clinical trials of the most promising treatments. We’re thrilled to partner with Michelle and the Medable team to bring our vision to life and help address this critical industry challenge together.” For more information about Every Cure: Watch Dr. Fajgenbaum’s talk at the Clinton Global Initiative here ; Click here to read a fireside chat between Dr. Longmire and Dr. Fajgenbaum; or Schedule a meeting with Dr. Longmire and Dr. Fajgenbaum at the 2023 J.P. Morgan Healthcare Conference by emailing lbarbadora@barbadoraink.com About Medable Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience and outcomes. Medable’s software has been named a Leader in the industry by both Everest Group and IDC. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Contacts +1 (610) 420-3413